Cosalane Analogs with Enhanced Potencies as Inhibitors of HIV-1 Protease and Integrase
Article 1995 en
Authors
MC
Mark Cushman
WG
W. Marek Gołębiewski
YP
Yves Pommier
Abstract
1 min read
Several new analogues of the novel anti-HIV agent cosalane have been synthesized and evaluated as inhibitors of HIV-1 integrase and protease, HIV-1 replication, HIV-1 and HIV-2 cytopathicity, HIV-1- and HIV-2-mediated syncytium formation, and cytopathicity of a variety of human pathogenic viruses. The congeners displayed enhanced potencies relative to cosalane itself as inhibitors of HIV-1 integrase and protease. The two most potent analogues against HIV-1 integrase displayed IC50 values of 2.2 microM, while the three most potent compounds against HIV-1 protease had IC50 values in the 0.35-0.39 microM range. In addition to its activity against HIV-1 and HIV-2 cytopathicity, cosalane inhibited the cytopathic effects of herpes simplex virus-1, herpes simplex virus-2, and human cytomegalovirus at concentrations that were well below the cytotoxic concentrations. Potentially useful antiviral activities were also revealed for some of the new cosalane congeners against influenza virus, Junin virus, and Tacaribe virus.
Zhaiwei Lin, Nouri Neamati, He Zhao, Yoshimitsu Kiryu, Jim A. Turpin, Claudia Aberham, Klaus Strebel, Kurt W. Kohn, Myriam Witvrouw, Christophe Pannecouque, Zeger Debyser, De Clercq Erik, William G. Rice, Yves Pommier, Terrence R. Burke
Alain Leydet, Christine Jeantet‐Segonds, Corinne Bouchitté, Céline Moullet, Bernard Boyer, Jean Pierre Roque, Myriam Witvrouw, José A. Esté, Robert Snoeck, Graciela Andreï, De Clercq Erik
Mark Cushman, Shabana Insaf, Gitendra C. Paul, Jeffrey A. Ruell, De Clercq Erik, Dominique Schols, Christophe Pannecouque, Myriam Witvrouw, Catherine A. Schaeffer, Jim A. Turpin, Karen Williamson, William G. Rice
Alain Leydet, Céline Moullet, Jean Pierre Roque, Myriam Witvrouw, Christophe Pannecouque, Graciela Andreï, Robert Snoeck, Johan Neyts, Dominique Schols, De Clercq Erik
Discussion(0)
No comments yet. Be the first to comment.